Skip to content

MK-0518 integrase inhibitor effective in treatment-naive patients

TNX-355, new entry inhibitor, effective in highly treatment-experienced patients

Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced

Kaletra monotherapy as effective as triple therapy for at least 18 months

Efavirenz more durable than Kaletra over two years in treament-naive patients

Access to treatment associated with declining stigma in Botswana

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor